Helen ACA - Khiron Life Interim Officer
| KHRNF Stock | USD 0.0001 0.00 0.00% |
Insider
Helen ACA is Interim Officer of Khiron Life Sciences
| Phone | 705 527 3564 |
| Web | https://khiron.ca |
Khiron Life Management Efficiency
The company has return on total asset (ROA) of (0.2079) % which means that it has lost $0.2079 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7468) %, meaning that it generated substantial loss on money invested by shareholders. Khiron Life's management efficiency ratios could be used to measure how well Khiron Life manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Howard CFA | Im Cannabis Corp | 59 | |
| Mark Baldyga | Biofrontera | N/A | |
| Matthew Mundy | RIV Capital | 39 | |
| Mark Sims | RIV Capital | N/A | |
| Oren Shuster | Im Cannabis Corp | N/A | |
| Hermann Lubbert | Biofrontera | 68 | |
| Advocate Harrosh | Im Cannabis Corp | N/A | |
| Eugene III | Biofrontera | 39 | |
| Mike Totzke | RIV Capital | N/A | |
| Ryan Kee | Grown Rogue International | 40 | |
| Obie Strickler | Grown Rogue International | 40 | |
| Peter Hatziioannou | RIV Capital | N/A | |
| Sean McNulty | RIV Capital | N/A | |
| Rinat Efrima | Im Cannabis Corp | 47 | |
| Amanda Rico | RIV Capital | N/A | |
| Adam August | Grown Rogue International | 45 | |
| Michael Ruscetta | Im Cannabis Corp | 55 | |
| Steven Lightman | Grown Rogue International | 66 | |
| Adam Pope | RIV Capital | N/A | |
| Erica CPA | Biofrontera | 39 | |
| Buddy Wilson | Grown Rogue International | N/A | |
Management Performance
| Return On Equity | -0.75 | |||
| Return On Asset | -0.21 |
Khiron Life Sciences Leadership Team
Elected by the shareholders, the Khiron Life's board of directors comprises two types of representatives: Khiron Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Khiron. The board's role is to monitor Khiron Life's management team and ensure that shareholders' interests are well served. Khiron Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Khiron Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Juan Alvarez, VP Regulations | ||
| Alvaro Torres, CEO CoFounder | ||
| ACA ACWA, Co Sec | ||
| Helen ACA, Interim Officer | ||
| Franziska Katterbach, Pres Europe | ||
| Manuel Buendia, VP Operations | ||
| Luis Chavez, Country Mexico | ||
| Marco Algorta, Country Uruguay |
Khiron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Khiron Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.75 | |||
| Return On Asset | -0.21 | |||
| Profit Margin | (1.90) % | |||
| Operating Margin | (1.08) % | |||
| Current Valuation | 9.19 M | |||
| Shares Outstanding | 216.39 M | |||
| Shares Owned By Insiders | 5.00 % | |||
| Shares Owned By Institutions | 0.23 % | |||
| Price To Book | 0.45 X | |||
| Price To Sales | 0.54 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Khiron Pink Sheet
Khiron Life financial ratios help investors to determine whether Khiron Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Khiron with respect to the benefits of owning Khiron Life security.